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Edited by Peter CresswellCytokines and chemokines are important regulators of
airway hyper-responsiveness, immune cell infiltration, and
inflammation and are produced when mast cells are stimulated
with interleukin-33 (IL-33). Here, we establish that the salt-
inducible kinases (SIKs) are required for the IL-33-stimulated
transcription of il13, gm-csf and tnf and hence the produc-
tion of these cytokines. The IL-33–stimulated secretion of IL-
13, granulocyte-macrophage colony stimulating factor, and
tumor necrosis factor was strongly reduced in fetal liver–
derived mast cells from mice expressing a kinase-inactive
mutant of SIK3 and abolished in cells expressing kinase-
inactive mutants of SIK2 and SIK3. The IL-33–dependent
secretion of these cytokines and several chemokines was also
abolished in SIK2/3 double knock-out bone marrow–derived
mast cells (BMMC), reduced in SIK3 KO cells but little
affected in BMMC expressing kinase-inactive mutants of SIK1
and SIK2 or lacking SIK2 expression. In SIK2 knock-out
BMMC, the expression of SIK3 was greatly increased. Our
studies identify essential roles for SIK2 and SIK3 in producing
inflammatory mediators that trigger airway inflammation. The
effects of SIKs were independent of IκB kinase β, IκB kinase β-
mediated NF-κB-dependent gene transcription, and activation
of the mitogen-activated protein kinase family members p38α
and c-jun N-terminal kinases. Our results suggest that dual
inhibitors of SIK2 and SIK3 may have therapeutic potential for
the treatment of mast cell–driven diseases.
According to the World Health Organization, the number
of asthma patients worldwide exceeds 200 million. Airway
inflammation is a feature of many asthma subtypes, so that
understanding the interplay between the immune system and
the cell types lining the airways is important. Mast cells have a
significant role in asthma because they migrate into the airway
smooth muscle, epithelium, and mucous glands of asthma
patients where they release mediators of asthma (1–3). Mast
cells, which are present in higher numbers in the airways of
asthmatics (4), drive the disease by releasing cytokines that
trigger airway inflammation, as well as histamine, prosta-
glandin D2, and leukotriene C4, which promote smooth
muscle constriction and mucus secretion by the lungs (5).* For correspondence: Philip Cohen, p.cohen@dundee.ac.uk.
© 2021 THE AUTHORS. Published by Elsevier Inc on behalf of American Society for
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Other immune cells, such as eosinophils, are also important in
late phase or chronic asthma (5–7).
Interleukin-33 (IL-33) is upregulated in and correlates with
disease severity in asthma patients (8, 9). It stimulates the secre-
tion of other cytokines, such as interleukin-13 (IL-13),
granulocyte-macrophage colony stimulating factor (GM-CSF),
and tumor necrosis factor (TNF) in mast cells (10, 11). IL-13
promotes airway obstruction through the overproduction of
mucus (12, 13), as well as airway hyper-responsiveness and the
infiltration of eosinophils into the lungs (12–14). GM-CSF has a
critical role in promoting the proliferation and maturation of
antigen-presenting cells involved in the presentation of allergens
to T cells (15). Indeed, airway administration of GM-CSF in vivo
was found to lower the threshold for the secretion of Th2 cyto-
kines, such as IL-13, and eosinophil infiltration into the lungs in
the house dust mite model of asthma and to increase IL-33 levels
in this model (16). GM-CSF can also act together with IL-33 to
promote the secretion of IL-13 in GM-CSF–derived macro-
phages and dendritic cells (17, 18). TNF has been implicated in
many aspects of airway pathology in asthma (2, 19), whereas a
number of chemokines promote the recruitment of additional
immune cells to the lungs (20, 21). For example, the chemokine
(C-C motif) ligand 24 (CCL24, also called eotaxin-2) stimulates
the recruitment of eosinophils (20), which are associated with
more severe forms of asthma. These findings have generated in-
terest in developing therapies aimed at neutralising these cyto-
kines or suppressing their production in asthma patients.
IL-33 is an interleukin-1 (IL-1) family member that exerts
its effects on cells by binding to the ST2 component of the IL-
33 receptor (22). Similar to IL-1, the interaction of IL-33 with
its receptor induces the recruitment of myeloid differentiation
factor 88 and IL-1 receptor–associated kinases 1, 2 and 4,
forming oligomeric complexes, termed myddosomes (23). This
leads to the activation of mitogen-activated protein (MAP)
kinases, such as p38α and c-jun N-terminal kinase 1 (JNK1)
and JNK2, and the IκB kinases (IKKs) which activate tran-
scription factors, such as NF-κB. The p38α MAP kinase is
required for the IL-33–stimulated secretion of IL-13, GM-CSF,
TNF, and the chemokines CCL3 and CCL4 (11, 24).
The salt-inducible kinases (SIKs) are constitutively active,
but their activity can be decreased by phosphorylation cata-
lyzed by cyclic AMP-dependent protein kinase, in response to
ligands that elevate intracellular cyclic AMP, such asJ. Biol. Chem. (2021) 296 100428 1
Biochemistry and Molecular Biology. This is an open access article under the CC
SIKs are essential for cytokine secretion in mast cellsprostaglandin E2 (25). The SIKs regulate cytokine production
in macrophages and dendritic cells by impinging on
myddosome-dependent processes (26–28). For example, SIK2
and SIK3 phosphorylate and inactivate cAMP response
element-binding protein (CREB)-regulated transcription co-
activator 3 in macrophages, preventing activation of the
transcription factor CREB that drives the production of anti-
inflammatory molecules, such as IL-10 (25, 26, 29). In this way
the SIKs antagonise a p38α-dependent pathway involving the
activation of mitogen- and stress-activated kinases 1/2, the
kinases that activate CREB (30). The SIKs also promote the
production of TNF and other cytokines in macrophages and
dendritic cells by an as yet unidentified mechanism (26–29).
In this article, we have identified new and essential roles for
the SIK family members, SIK2 and SIK3, in the production ofA
B
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Figure 1. SIK inhibition suppresses IL-33–dependent secretion of IL-13, GM
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necrosis factor.
2 J. Biol. Chem. (2021) 296 100428cytokines and chemokines by mast cells, which suggests that
inhibitors of these protein kinases may have therapeutic po-
tential for the treatment of mast cell–driven diseases, such as
asthma.
Results
SIK inhibition suppresses IL-33–dependent cytokine secretion
from mast cells
We initially studied the IL-33–dependent secretion of IL-13,
GM-CSF, and TNF from WT bone marrow–derived mast cells
(BMMCs) (Fig. 1). The secretion of IL-13 and GM-CSF was
elevated 2 h after stimulation with IL-33 and continued to
accumulate in the culture medium up to 6 h after stimulation
(Fig. 1, A and B). In contrast, TNF secretion was detectable-CSF and TNF in BMMC. A–C, BMMCs from WT mice were incubated for 1 h
d panels) or 3 μM MRT199665 (closed triangles, right hand panels) and then
TNF (C) secreted into the culture medium was measured as in Experimental
xperiment but plotted in separate panels for clarity and are presented as the
btained in three independent experiments. Statistical analysis is represented
st, comparing each inhibitor to control; * p < 0.05, ** p < 0.01, *** p < 0.001.
lony stimulating factor; IL, interleukin; SIK, salt-inducible kinase; TNF, tumor
SIKs are essential for cytokine secretion in mast cellsafter 1 h and peaked after 2 h (Fig. 1C). The IL-33–dependent
secretion of all three cytokines was drastically decreased by
treatment with HG-9-91-01 or MRT199665 (Fig. 1), which are
structurally unrelated small molecule inhibitors of all three
SIK isoforms (26).
Complete suppression of cytokine secretion was observed
when HG-9-91-01 and MRT199665 were used at 0.5 μM and
3 μM, respectively (Fig. S1, A–C). These concentrations were
used for all subsequent studies, unless indicated otherwise and
are similar to those previously found to inhibit SIKs in mac-
rophages (26). Stimulation of mast cells for 6 h with IL-33 in
the absence of inhibitors decreased the number of mast cells






Figure 2. SIK inhibition suppresses IL-33–dependent production of il13, g
Figure 1 except that, at the times indicated, cells were lysed and the mRN
Experimental procedures. The figures show the mRNA level relative to gapd
biological replicates. The results using HG-9-91-01 and MRT199665 are from
results were obtained in two independent experiments. Statistical analysis is r
comparison test, comparing each inhibitor to control; * p< 0.05, ** p< 0.01, ***
were then treated with 50 μM DRB and 5 μg/ml actinomycin D to block transcr
left panel), 3 μMMRT199665 (closed triangles, right panel), or 1 μM VX745 (closed
gm-csf (E), and tnf (F) mRNA levels were measured, normalized to gapdh mRNA
inhibition. The results are presented as the mean and standard deviation of t
ments. The results using HG-9-91-01, MRT199665 and VX745 are from the
dichlorobenzimidazole 1-β-D-ribofuranoside; BMMC, bone marrow-derived m
interleukin; SIK, salt-inducible kinase; TNF, tumor necrosis factor.in the absence of IL-33 (Fig. S1D). The inclusion of HG-9-91-
01 and MRT199665 improved cell viability in IL-33–stimu-
lated cells, indicating that these compounds are not toxic and
that the suppression of IL-13, GM-CSF, and TNF secretion
does not result from the inhibitors causing cell death
(Fig. S1D). These results suggested that the catalytic activity of
one or more SIK isoforms was required for the secretion of IL-
13, GM-CSF, and TNF from BMMCs.
SIK inhibition suppresses IL-33–dependent transcription of
il13, gm-csf, and tnf
To investigate how IL-33 induced the production of IL-13,
GM-CSF, and TNF, we studied the formation of the mRNAsm-csf, and tnf mRNA in BMMC. A–C, The experiment was performed as in
A encoding IL-13 (A), GM-CSF (B), and TNF (C) measured as described in
h mRNA and are presented as the mean and standard deviation of four
the same experiment but plotted in separate panels for clarity, and similar
epresented by repeated measures two-way ANOVA with Dunnett’s multiple
p< 0.001. D–F, WT BMMCs were incubated for 2 h with 10 ng/ml IL-33. Cells
iption without (control, open circles) or with 0.5 μM HG-9-91-01 (closed circles,
squares, right panel). At the times indicated, cells were lysed, and the il13 (D),
, and plotted relative to mRNA levels measured at the point of transcription
hree replicates. Similar results were obtained in three independent experi-
same experiment, but plotted in separate panels for clarity. DRB, 5,6-
ast cell; GM-CSF, granulocyte-macrophage colony stimulating factor; IL,
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SIKs are essential for cytokine secretion in mast cellsencoding these cytokines (Fig. 2). IL-33 stimulated an increase
in il13 and gm-csf mRNA, which occurred after 1 h, peaked
after 2 h and was sustained for at least a further 2 h (Fig. 2, A
and B). In contrast, tnfmRNA production peaked after 1 h and
then declined rapidly (Fig. 2C). These results are consistent
with the effects of IL-33 on cytokine secretion (Fig. 1).
We next investigated the rate at which these mRNAs
declined when gene transcription was arrested by the addition
of actinomycin D and 5,6-dichlorobenzimidazole 1-β-D-ribo-
furanoside. The SIK inhibitors induced only a modest increase
in the rate of mRNA decay that was not statistically significant
(Fig. 2, D–F). In contrast, and as expected from previous
studies (11), the p38α MAP kinase inhibitor VX745 increased
the rate of tnf mRNA decay and strikingly increased the rate of
decay of gm-csf mRNA but had no effect on il13 mRNA decay
(Fig. 2, D–F). Taken together, the results suggested that SIKs
regulate transcription of the genes encoding these cytokines
with little effect on mRNA stability.
IL-33–dependent cytokine production in mast cells from mice
deficient in the activity or expression of SIKs
The compounds HG-9-91-01 and MRT199665 inhibit all
three SIK isoforms with similar potency (26). To identify the
SIK isoform(s) relevant to IL-33–dependent cytokine pro-
duction, we studied mast cells from mice expressing kinase-
inactive mutants of SIKs (29) and mast cells from SIK
knock-out (KO) mice. The kinase-inactive SIK2[T175A]/SIK3
[T163A] double knock-in mouse dies at a late stage of em-
bryonic development (29), and so, studies with this double
knock-in were performed in mast cells derived from fetal
livers, in which the SIK inhibitors have a similar effect to that
observed in BMMC (compare Fig. S2 with Fig. 1). We found
that the IL-33–dependent secretion of IL-13, GM-CSF, and
TNF was virtually abolished in SIK2[T175A]/SIK3[T163A]
double knock-in fetal liver–derived mast cells (FLMCs) (Fig. 3,
A–C), and similar results were obtained in FLMC from SIK2/
SIK3 double KO mice (Fig. 3, D–F). The IL-33–stimulated
secretion of IL-13 and TNF was strongly reduced (Fig. 3, A and
C), and the secretion of GM-CSF partially reduced (Fig. 3B) in
FLMC from SIK3[T163A] mice.
These results indicate that SIK1 is unable to compensate for
the combined loss of SIK2/3 expression or catalytic activity in
FLMC and is consistent with quantitative proteomic experi-
ments that we have carried out in BMMC. These studies showed
that mast cells express 5973 ± 109 copies of SIK3 and 675 ± 29
copies of SIK2 per cell, but SIK1-specific peptides were not
detected in any of these experiments. Moreover, we were unable
to detect a protein with the molecular mass of SIK1 by immu-
noblotting of BMMC using two different commercially available
SIK1 antibodies (see Experimental procedures). This suggests
that either SIK1 is not expressed in mast cells or that the level of
expression is very low. Consistent with this conclusion, the loss
of SIK1 catalytic activity in BMMC had no effect on the secre-
tion of IL-13, GM-CSF, or TNF (Fig. S3).
The SIK1[T182A]/SIK2[T175A] double knock-in mice are
viable, and we therefore studied their contribution to IL-33–4 J. Biol. Chem. (2021) 296 100428dependent cytokine production in BMMC from adult mice.
These experiments showed that the loss of both SIK1 and SIK2
catalytic activity did not have a statistically significant effect on
IL-13 or GM-CSF secretion (Fig. 4, A and B) or on the level of
il13 and gm-csf mRNA (Fig. S4, A and B), indicating that
cytokine production in these cells is controlled by SIK3. The
contribution of SIK3 may be enhanced by the modest (50 %)
increase in its expression that occurs in BMMC from SIK1
[T182A]/SIK2[T175A] double knock-in mice (Fig. S5A). This is
probably caused by the loss of SIK2 catalytic activity because
there was no increase in SIK3 in extracts from SIK1[T182A]
single knock-in BMMC (Fig. S5B). In SIK3 KO BMMC, the
secretion of IL-13 and GM-CSF was reduced partially (Fig. 4, C
and D), suggesting that another SIK isoform is compensating
for the loss of SIK3. This is presumably SIK2, as the KO of both
SIK2 and SIK3 abolished cytokine secretion. Similar to BMMC
from SIK1[T182A]/SIK2[T175A] double knock-in mice, the
KO of SIK2 alone did not have a statistically significant effect on
the secretion of IL-13 or GM-CSF (Fig. 4, C and D). This ap-
pears to be because of compensation by SIK3, whose expression
is greatly increased in SIK2 KO BMMC (Fig. S5C). In contrast,
the expression of SIK2 was little affected in BMMC from SIK3
KO mice, but quantitation was not possible because another
protein migrating very close to but slightly faster than SIK2 was
recognized nonspecifically by the antibody (Fig. S5C).
In contrast to IL-13 and GM-CSF, the secretion of TNF
(Fig. 4, E and F) was reduced significantly in SIK1[T182A]/
SIK2[T175A] double knock-in BMMC, as well as in SIK3 KO
BMMC, indicating the involvement of more than one SIK
isoform. These are presumably SIK2 and SIK3 because the KO
of both SIK2 and SIK3 abolished cytokine secretion. The
partial suppression of TNF secretion in BMMC from SIK2/
SIK3 double KO mice and apparent absence of SIK1 in these
cells suggest that another protein kinase may compensate for
the absence of SIK2 and SIK3 when the expression of both of
these isoforms is ablated. However, such compensation does
not happen in FLMC expressing the kinase-inactive SIK2
[T175A] and SIK3[T163A] mutants or in FLMC lacking any
expression of SIK2 and SIK3 (Fig. 3, C and F).
SIK2/3-mediated, IL-33–dependent cytokine secretion occurs
independently of p38α or JNK MAP kinases, IKKβ, or NF-κB
The cell surface levels of ST2 were unaffected by SIK in-
hibitors or in SIK2/3 double KO cells (Fig. S6, A and B),
suggesting the SIKs control cytokine secretion “downstream”
of the receptor. The p38α MAP kinase is required for cytokine
and chemokine secretion in BMMC (11, 24). We found that
SIK inhibitors did not affect the IL-33–stimulated phosphor-
ylation (activation) of the MAP kinase family members p38α or
JNK, indicating that the suppression of cytokine production by
these compounds was not explained by inhibition of the
pathway leading to the activation of these MAP kinases
(Fig. S6, C and D). Similar results were obtained in BMMC
from SIK2/3 double KO mice (Fig. S6, E and F). In addition,
JNK-IN-8, a JNK inhibitor, suppressed the phosphorylation of







Figure 3. SIK3 catalytic activity is critical for IL-13, GM-CSF, and TNF secretion in FLMC. A–F, FLMC from WT embryos, embryos expressing the kinase-
inactive mutants of SIK3 (SIK3[T163A]) or both SIK2 and SIK3 (SIK2[T175A]/SIK3[T163A]) as well as SIK2/SIK3 double KO embryos were stimulated for the
times indicated with 10 ng/ml IL-33. The concentrations of IL-13 (A, D), GM-CSF (B, E), and TNF (C, F) in the cell culture medium were then analyzed. The
results in A–F are from a single experiment using FLMC from four WT, four SIK3[T163A], six SIK2[T175A]/SIK3[T163A], and four SIK2/3 KO mice and are
plotted as the mean and standard deviation. Similar results were obtained in two independent experiments. The statistical analysis is represented by
repeated measures two-way ANOVA with Dunnett’s multiple comparison test comparing all mutants to WT mast cells; * p < 0.05, ** p < 0.01. BMMC, bone
marrow-derived mast cell; FLMC, fetal liver–derived mast cell; GM-CSF, granulocyte-macrophage colony stimulating factor; IL, interleukin; KO, knock-out; SIK,
salt-inducible kinase; TNF, tumor necrosis factor.
SIKs are essential for cytokine secretion in mast cellssecretion of IL-13 and GM-CSF, although TNF secretion was
reduced by 70 % after 2 h and 35 % after 6 h (Fig. S7). Taken
together, our results indicate that the SIKs exert their effects
on cytokine secretion in mast cells by a mechanism that is
independent of these MAP kinases. It should be noted that
JNK-IN-8 does not affect the IL-33–stimulated phosphoryla-
tion of JNKs but nevertheless decreases their electrophoretic
mobility because of its covalent mechanism of inhibition (31).
The IL-33–stimulated phosphorylation of p105/NF-κB1, a
substrate of IKKβ (32, 33), was not reduced by the SIK in-
hibitors or in SIK2/3 double KO BMMC (Fig. S6, C and E),
indicating that SIKs are not required at any step in the pathway
leading to activation of the IKKβ component of the canonical
IKK complex. Moreover, SIK inhibitors had little effect on
IKKβ-mediated NF-κB–dependent gene transcription(Fig. S8A) at concentrations that completely prevented IL-33–
stimulated cytokine secretion (Figs. 1 and S1). In contrast, two
structurally unrelated small molecule inhibitors of IKKβ
blocked IL-33–stimulated NF-κB–dependent transcription of
a luciferase reporter gene, as expected (Fig. S8A). We also
investigated how IKKβ inhibitors affected IL-33–stimulated
cytokine secretion. GM-CSF and TNF secretions were reduced
by about 50 %, whereas IL-13 secretion was unaffected (Fig. S8,
B–D). In summary, our results indicate that the activation of
IKKβ, IKKβ activity, and IKKβ-mediated, NF-κB–dependent
gene transcription is not required for IL-33–stimulated IL-13
production in mast cells but may contribute to GM-CSF and
TNF induction by an SIK-independent mechanism. Taken
together, our results indicate that the SIKs exert their effects







Figure 4. IL-33–dependent secretion of cytokines in BMMC from SIK1/2 double knock-in, SIK3 knock-out, and SIK2/3 double knock-out mice. A and
B, The experiments were performed as in Figure 1 using BMMCs differentiated from WT, SIK1[T182A]/SIK2[T175A] double knock-in mice and SIK2/SIK3
double KO mice. After stimulation for the times indicated with 10 ng/ml IL-33, IL-13 (A), and GM-CSF (B) secreted into the culture medium was analyzed.
C and D, BMMCs from SIK2 KO, SIK3 KO, SIK2/3 double KO, and WT mice were stimulated with IL-33 and cytokine secretion measured as in A and B. E and F,
As for A-D except that TNF secretion was measured. The results shown are the mean and standard deviation from four mice per genotype. Similar results
were obtained in two independent experiments. The statistical analysis is represented by repeated measures two-way ANOVA with Dunnett’s multiple
comparison test, comparing SIK1[T182A]/SIK2[T175A] or SIK2/3 KO BMMC to WT BMMC (A, B, E) or comparing SIK2 KO, SIK3 KO or SIK2/3 KO BMMC to WT
BMMC (C, D, F); * p < 0.05, ** p < 0.01, *** p < 0.001. BMMC, bone marrow-derived mast cell; GM-CSF, granulocyte-macrophage colony stimulating factor; IL,
interleukin; KO, knock-out; SIK, salt-inducible kinase; TNF, tumor necrosis factor.
SIKs are essential for cytokine secretion in mast cellslargely independent of IKKβ and IKKβ-mediated, NF-κB-
dependent gene transcription.
SIK activity is required for the secretion of several chemokines
from mast cells
Mast cells also secrete chemokines, which have important
roles in promoting the recruitment of immune cells to the
lungs and therefore in establishing lung inflammation and
bronchial hyper-responsiveness (20, 21). The chemokines
CCL2 (also known as monocyte chemoattractant protein-1),
CCL3 (also known as macrophage inflammatory protein-1α),
and CCL4 (macrophage inflammatory protein-1β) were
detected in the culture medium of WT BMMCs after stim-
ulation for 1 h with IL-33, whereas CCL24 was detected after
2 h (Fig. 5, A–D). CCL3, CCL4, and CCL24 continued to
accumulate for up to 8 h after stimulation (Fig. 5, B–D), but
CCL2 secretion became near maximal after 2 h (Fig. 5A).6 J. Biol. Chem. (2021) 296 100428The secretion of all four chemokines was strongly sup-
pressed by SIK inhibitors (Fig. 5, A–D) or in SIK2/3 double
KO BMMC (Fig. 5, E–H). We were unable to detect any
CCL11 (eotaxin-1) in the culture medium after stimulation
with IL-33.
In contrast to the cytokines mentioned in the preceding
paragraph, the SIK inhibitors did not block the secretion of
chemokine (C-X-C motif) ligand 2 (also called MIP-2)
(Fig. S9A), which is the mouse ortholog of human IL-8.
Indeed, the secretion of chemokine (C-X-C motif) ligand 2
was actually elevated in the SIK3 KO or SIK2/SIK3 double KO
mice (Fig. S9B).
Discussion
Our earlier studies in macrophages and dendritic cells
established critical roles for the SIK subfamily of protein ki-









Figure 5. SIK activity is required for CCL2, CCL3, CCL4, and CCL24 secretion in BMMC. A–D, WT BMMCs were incubated for 1 h without (open circles,
control) or with 0.5 μM HG-9-91-01 (closed circles) or 3 μMMRT199665 (closed triangles), then stimulated with 10 ng/ml IL-33. The concentrations of CCL2 (A),
CCL3 (B), CCL4 (C), and CCL24 (D) in the cell culture medium were measured. The results shown are mean and standard deviation from four biological
replicates (A–C) or three biological replicates (D) with similar results obtained in two independent experiments. Statistical analyses are shown as repeated
measures two-way ANOVA with Dunnett’s multiple comparison test, comparing HG-9-91-01 (*) or MRT199665 (#) to control; *,# p < 0.05, **,## p < 0.01,
***,### p < 0.001. E–H, BMMCs generated from WT, SIK1[T182A]/SIK2[T175A] double knock-in, SIK3 KO and SIK2/SIK3 double KO mice were stimulated for the
times indicated with 10 ng/ml IL-33. The concentrations of CCL2 (E), CCL3 (F), CCL4 (G), and CCL24 (H) in the cell culture medium were measured as
described in Experimental procedures. The results shown are the mean and standard deviation from four biological replicates with similar results obtained
in two independent experiments. Statistical analyses are shown as repeated measures two-way ANOVA with Dunnett’s multiple comparison test, comparing
SIK1[T182A]/SIK2[T175A], SIK3 KO or SIK2/3 KO to WT BMMCs; * p < 0.05, ** p < 0.01, *** p < 0.001. BMMC, bone marrow-derived mast cell; CCL, chemokine
(C-C motif) ligand; GM-CSF, granulocyte-macrophage colony stimulating factor; IL, interleukin; KO, knock-out; SIK, salt-inducible kinase.
SIKs are essential for cytokine secretion in mast cellsof proinflammatory and antiinflammatory cytokines by TLR-
activating ligands (26, 29). The inhibition of both SIK2 and
SIK3 increased the production of the antiinflammatory cyto-
kine IL-10 and drastically reduced the production of major
proinflammatory cytokines, such as IL-6 and IL-12, (see the
start of the text). These and other findings (34) suggested thatdrugs inhibiting both SIK2 and SIK3 might have therapeutic
potential for the treatment of inflammatory and autoimmune
diseases. Interestingly, the biotechnology company Galapagos
disclosed on October 27th 2020 that compounds from their
“Toledo” program target the SIK family of protein kinases and
that a dual SIK2/SIK3 inhibitor GLPG3970 had passed Phase IJ. Biol. Chem. (2021) 296 100428 7
SIKs are essential for cytokine secretion in mast cellstrials and would soon be entering advanced clinical trials for
psoriasis, rheumatoid arthritis, and ulcerative colitis. The
present study which shows that the combined inhibition of
SIK2/3 suppresses the production of a number of cytokines
and chemokines that contribute to the pathogenesis of asthma
now suggests that GLPG3970 and/or related compounds may
be worth exploring as potential treatments for asthma patients
who are refractory to the corticosteroid therapies that are in
widespread use. The efficacy of antibodies that target a single
cytokine has proved disappointing in advanced clinical trials
for asthma, and several such trials have been stopped (35–38).
Drugs that suppress the production of many cytokines and
chemokines that are important contributors to asthma pa-
thology (such as SIK2/3 inhibitors) may have greater efficacy.
Interestingly, genome-wide association studies have identified
single nucleotide polymorphisms within the regions contain-
ing SIK genes that are associated with asthma or with allergic
diseases such as hay fever and eczema (39).
In the present study, we found that SIK2/3 inhibition
abolished transcription of the genes encoding IL-13, GM-CSF,
and TNF, implying that a SIK2/3-catalyzed phosphorylation
event(s) is essential for this process. The transcription factors
NF-κB and IRF5, which are essential for the production of
many proinflammatory cytokines in macrophages, are acti-
vated by IKKβ-catalyzed phosphorylation events (40, 41). We
found that SIK inhibitors did not affect IKKβ activation or
activity, indicating that SIKs are not required at any step be-
tween the IL-33 receptor and the activation of the IKKβ
component of the canonical NF-κB complex (Fig. S6, C and E).
The SIK inhibitors also had little effect on IL-33–stimulated
NF-κB–dependent gene transcription (Fig. S8A) at concen-
trations that abolish IL-13, GM-CSF, and TNF production
(Fig. S1, A–C). Conversely, IKKβ inhibitors blocked IL-33–
stimulated NF-κB–dependent gene transcription (Fig. S8A)
but had no effect on IL-33–stimulated IL-13 secretion
(Fig. S8B) and only reduced GM-CSF and TNF secretion by 50
% in BMMCs (Fig. S8, C and D). Taken together, our results
establish that SIKs do not regulate cytokine gene transcription
via IKKβ or IKKβ-stimulated activation of NF-κB–dependent
gene transcription. However, our results do not exclude the
possibility that SIKs regulate IL-33–stimulated cytokine and
chemokine production by modulating the noncanonical NF-
κB pathway, which requires IKKα and not IKKβ activity.
It has been reported by others (42) that SIKs phosphorylate
and inactivate histone deacetylase 4 and histone deacetylase 5,
leading to increased acetylation of the p65 subunit of NF-κB,
which is thought to stimulate its ability to bind to gene pro-
moters and transcribe genes. Such genes include those
encoding proinflammatory cytokines, including tnf (42). The
results presented in this article (Figs. S6 and S8) indicate that
this is not the mechanism by which SIKs mediate the tran-
scription of genes encoding cytokines and chemokines in mast
cells, otherwise the SIK inhibitors would have been expected to
suppress IL-33–stimulated NF-κB–dependent gene
transcription.
It is well established that the activation of p38α is required
for the production of IL-13, GM-CSF, TNF, CCL3, and CCL48 J. Biol. Chem. (2021) 296 100428in mast cells and that it stimulates GM-CSF and TNF pro-
duction by stabilizing the mRNAs encoding these cytokines
and not by regulating the transcription of their genes (11, 24).
We found that SIK inhibition, or ablation of the expression of
both SIK2 and SIK3, had no effect on the IL-33–stimulated
activation of p38α (Fig. S6, C–F), and SIK inhibition did not
accelerate the decay of GM-CSF or TNF significantly (Fig. 2, E
and F). Our studies therefore suggest that SIKs are unlikely to
control cytokine or chemokine gene transcription via p38α.
Similarly, a JNK inhibitor blocked the phosphorylation (acti-
vation) of the transcription factor c-Jun (Fig. S7A) without
affecting the secretion of IL-13 or GM-CSF (Fig. S7, B–D).
Taken together, our results exclude the possibility that SIKs
control il13 or gm-csf gene transcription in mast cells by
suppressing the MAP kinase family members p38α and JNK.
Identifying the transcription factor or transcriptional co-
activator(s) whose phosphorylation by SIK2/3 is required for
cytokine and chemokine gene transcription in mast cells is a
key outstanding question that has yet to be solved.
Experimental procedures
Materials
Recombinant murine IL-3 and IL-33 were purchased from
Peprotech, reconstituted in sterile water, and stored in aliquots
at −80 C. The structures of HG-9-91-01 and MRT199665 and
their characterization as SIK inhibitors have been described
previously (26). The IKKβ inhibitors BI605906 and PS1145, the
p38α inhibitor VX745, and the JNK inhibitor JNK-IN-8 were
synthesized by Natalia Shpiro in our unit. The protein kinase
inhibitors used in this study can be obtained from MRC PPU
Reagents and Services (https://mrcppureagents.dundee.ac.uk/).
Actinomycin D was purchased from Cambridge Bioscience and
5,6-dichlorobenzimidazole 1-β-D-ribofuranoside from Sigma.
Generation of mice
SIK1[T182A] (Sik1tm1.1 Arte), SIK2[T175A] (Sik2tm1.1 Arte),
and SIK3[T163A] (Sik3tm1.1 Arte) knock-in mice expressing
catalytically inactive mutants of each SIK were generated by
Taconic Biosciences and were characterized previously (29).
The SIK2[T175A] mice contain LoxP sites flanking exons 5 to
7 of the sik2 gene, with recombination at this site resulting in
loss of these exons (corresponding to amino acid residues
160–316) and a frame-shift mutation affecting the subsequent
exons. After germline expression of a Cre transgene by
crossing to the Cre Deleter strain (C57BL/6-Gt(ROSA)
26Sortm16(cre)Arte, Taconic Biosciences), the Cre was bred out of
the line, and mice testing negative for Cre expression for at
least three generations were used as SIK2 KO mice.
To generate SIK3flox/flox mice, C57Bl/6N-Sik3tm1a(EUCOMM)
Hmgu/Wtsi mice were purchased from the European Conditional
Mouse Mutagenesis Program (EUCOMM). The targeted SIK3
allele contained a cassette expressing LacZ and a neomycin-
resistance gene flanked by Frt sites (43). These mice were
bred to those expressing a Flp transgene (Taconic Biosciences),
resulting in loss of the LacZ-neomycin resistance cassette and
generation of a sik3flox allele. To generate mice that do not
SIKs are essential for cytokine secretion in mast cellsexpress SIK3 within the hematopoietic lineages, SIK3flox/flox
mice were bred to mice expressing a Cre transgene driven by
the Vav promoter (44). This deletes exon 5 of sik3 (encoding
amino acid residues 226–247) and causes frame-shift muta-
tions affecting the subsequent exons and hence disrupts the
gene.
SIK2 KO/SIK3flox/flox mice were generated by crossing
SIK2ko/+ and SIK3flox/flox mice to produce a mouse carrying both
the sik2ko and sik3flox alleles. Both sik2 and sik3 are located on
chromosome 9 separated by approximately 4.6 Mb, and so a
recombination event is required to link the sik2ko and sik3flox
mutations. This required multiple rounds of breeding using
SIK3flox/flox and SIK2ko/+SIK3flox/+ mice before a SIK2ko/+SIK3-
flox/flox mouse was detected. SIK2ko/+SIK3flox/flox mice were bred
to mice expressing a Cre transgene driven by the Vav promoter
(44). In this article, SIK3flox/floxVavcre+ and SIK2ko/koSIK3flox/
floxVavcre+ mice are termed SIK3 KO and SIK2/3 double KO
mice, respectively, and complete loss of SIK2 and SIK3 protein
expression in BMMCwas verified by immunoblotting (Fig. S5C).
SIK3flox/floxVavcre+ females are infertile, and the Vav pro-
moter can result in Cre expression in the testes (44), therefore
SIK3flox/+Vavcre+ or SIK2ko/koSIK3flox/+Vavcre+ females were
used to maintain these lines.
WT mice from the relevant SIK line or the SIK3+/+Vavcre+
(WT Vavcre+) mice were used for control experiments as indi-
cated in the figure legends. Allmiceweremaintained on aC57Bl/
6J background using mice obtained from Charles River Labora-
tories UK, and routine genotyping was carried out on genomic
DNA from ear biopsy specimens. Primers used for genotyping
SIK knock-inmicewere published previously (29). The following
primers were used for genotyping SIK KO mice; aaga-
gagtgtgggactaacttgg, cttaaaagctgggcatagtgg and tgttctctaag-
catgctaactactagg for SIK2 KO; gctgaagacgtggtgtggcag and
gcaggtaacatttctgcttccagac for SIK3flox/flox; ctccaacctgctgactgtgc
and caccagggacacagcattgg for Vavcre.
Animals were maintained under specific pathogen-free
conditions consistent with EU and UK regulations. Mice
were housed in individually ventilated cages at 21 C, 45 to 55
% humidity, and a 12/12 h light/dark cycle, with free access to
food (R&M3) and water. This work was performed under a
U.K. Home Office Project Licence awarded after recommen-
dation by the University of Dundee Ethical Review Committee.
Mast cell culture
BMMC were generated as described (45), using bone
marrow collected from femurs and tibias of 3 to 6 months old
mice. Fetal livers were differentiated into FLMCs. The fetal
livers were dissected from embryos at E14.5-E16.5, dispersed
to single cell suspensions in PBS using a 70 μm cell strainer,
pelleted at 300g for 5 min at 21 C, and re-suspended in 1.5 ml
freezing media (90 % [v/v] fetal bovine serum, 10 % [v/v]
dimethyl sulfoxide) per liver. Cells were then frozen at −80 C
for 24 h before transferring to liquid nitrogen. When sufficient
fetal liver cells from each genotype had been collected, they
were thawed rapidly in a 37 C water bath and diluted with
BMMC media (45) at 37 C to reduce the dimethyl sulfoxideconcentration to 1.5 % (v/v). Fetal liver cells were pelleted as
described above, re-suspended in 15 ml BMMC media, and
cultured as for BMMC.
Mast cells were seeded (typically at 106 cells/ml) in media
containing 30 ng/ml IL-3 because this is required for their
viability and for the expression of ST2 on the cell surface (46),
and cells were rested for 4 h before experimentation.
Flow cytometry
Mast cell purity was monitored by flow cytometry (Figs. S10
and S11) using a FACSCanto (BD Biosciences). 4 x 105 cells
were collected, pelleted, washed in 1 ml PBS containing 1 %
(w/v) bovine serum albumin, and suspended in 50 μl of the
same buffer containing 1 μl of anti-CD16/CD32 (BD Bio-
sciences, clone 2.4G2). After 10 min at 4 C, a further 50 μl of
buffer containing the following stains was added and incubated
for 30 min at 4 C; 0.25 μl of anti-c-kit-PE (eBioscience, clone
2B8), 0.25 μl of anti-FcεR1-FITC (eBioscience, clone MAR-1)
and 0.25 μl of anti-ST2-BV421 (BioLegend, clone DIH9).
The cells were washed twice with PBS containing 1 % (w/v)
bovine serum albumin and re-suspended in buffer containing
0.1 μM TO-PRO-3 Iodide (Invitrogen).
The gating strategy for mast cells is shown in Figure S10. As
reported previously (47), the expression of the cell surface
mast cell markers FcεR1 and c-kit was similar in BMMCs and
FLMCs (Fig. S11A). In addition, BMMCs and FLMCs
expressed identical levels of the IL-33 receptor, ST2 on their
cell surface (Fig. S11, B and C). On the other hand, FLMCs
appear more granular than BMMCs as determined by side
scatter on the flow cytometer (Fig. S11D) (47). The purity of
the mast cells used for experiments ranged from 80 to 95 %
and averaged >85 % purity. For cell counting, mast cell cul-
tures were diluted 1:10 in PBS containing 1 μg/ml DAPI
(Thermo Fisher) and analyzed using FACSVerse (BD Bio-
sciences) or NovoCyte (ACEA Biosciences). Data collected via
flow cytometry were analyzed using FlowJo software version 10
(Tree Star).
Immunoblotting
Mast cells were lysed in 50 mM Tris/HCl pH 7.4, 1 mM
EDTA, 1 mM EGTA, 50 mM sodium fluoride, 5 mM sodium
pyrophosphate, 10 mM sodium β-glycerol 1-phosphate, 1 mM
dithiothreitol, 1mMsodiumorthovanadate, 0.27M sucrose, 1%
(v/v) Triton X-100, 1 μg/ml aprotinin, 1 μg/ml leupeptin, 1 mM
phenylmethylsulphonyl fluoride, and cell lysates clarified by
centrifugation at 17,000g for 10 min at 4 C. The protein con-
centrations of the supernatants (cell extract) were determined
using the Bradford assay, and 15 to 20 μg of cell extract was
separated by SDS-PAGE.Where indicated in the figure legends,
10 mM MgCl2, 1 % (w/v) SDS and 0.05 % (v/v) Benzonase
nuclease were added to the lysis buffer, and protein concen-
trations of the cell extracts were determined using BCA assay. In
these experiments, 40 to 50 μg of cell extract was separated by
SDS-PAGE. Proteins were transferred to polyvinylidene
difluoride membranes, immunoblotted, and visualized by
chemiluminescence using enhanced chemiluminescenceJ. Biol. Chem. (2021) 296 100428 9
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(Bio-Rad Laboratories). Densitometric analysis was performed
using Image Lab 6.1 (Bio-Rad Laboratories). Antibodies were
purchased from the following suppliers: anti-GAPDH (#2118),
anti-SIK2 (#6919), anti-p38 (#9212), anti-phospho p105/NF-
κB1 (Ser932) (#4806), anti-phospho p38 (Thr180/Tyr182)
(#9211), anti-phospho c-Jun (Ser63) (#9261), anti-phospho
JNK1/2 (Thr183/Tyr185) (#9251), and horseradish
peroxidase-conjugated anti-rabbit antibodies from Cell
Signaling Technology. Anti-SIK1 antibodies were obtained
from Abcam (ab64428) and Santa Cruz (sc-83754). An anti-
SIK3 antibody was raised in house against amino acid residues
926 to 1038 of SIK3 (sheep S373D, bleed 3) and can be obtained
from MRC PPU Reagents and Services (https://
mrcppureagents.dundee.ac.uk/). Horseradish peroxidase-
conjugated anti-sheep secondary antibody was from Thermo
Scientific.
RNA isolation and QPCR
RNA was isolated from mast cells using the MicroElute
Total RNA kit (VWR) following the Manufacturers’ in-
structions. Reverse transcription to generate cDNA was per-
formed using the iScript cDNA synthesis kit (Bio-Rad
Laboratories) using 300 to 500 ng total RNA. SsoFast Eva-
Green Supermix (Bio-Rad Laboratories) was used on a
CFX384 RT-PCR machine (Bio-Rad Laboratories) to quantify
cDNA products. The expression of each gene was normalized
to mRNA levels of gapdh using 2
ˇ
(Ctgapdh-Ctgene of interest). The
following primers were used for qPCR: gapdh F, tgcaccac-
caactgcttag; gapdh R, gatgcagggatgatgttc; gm-csf F, gcaga-
caggagtgttgctct; gm-csf R, tgaaattgccccgtagaccc; il13 F,
gcagcagcttgagcacattt; il13 R, gcagacaggagtgttgctct; tnf F,
cagaccctcacactcagatcatc; tnf R, ggctacaggcttgtcactcg.
Secretion assays
Cytokines in cell-free cell culture medium were analyzed
using the Bio-Plex Pro Assay System (Bio-Rad Laboratories),
Luminex 200 machine, and xPONENT 4.1 software (Luminex
Corporation). The expression of Cre recombinase in WT
Vavcre+ BMMCs did not affect the IL-33–stimulated secretion
of cytokines from the cells (Fig. S12), and so WT mast cells not
expressing Cre recombinase were used as controls, unless
otherwise indicated.
Luciferase assays
To study NF-κB–dependent transcription, 4 million mast
cells were transfected with 2 μg NF-κB–dependent reporter
plasmid (PRDII elements from the IFNβ promoter cloned into
the pLuc-MCS vector, a kind gift from Professor Katherine
Fitzgerald, School of Medicine, University of Massachusetts)
(48) and 0.4 μg pTK-renilla luciferase (Stratech) plasmid.
Transfections were performed by electroporation using Cell
Line Nucleofector kit V and programme T-030 on a Nucleo-
fector II device (Lonza Bioscience). Cells were rested for 12 h
posttransfection before experimentation. Luciferase activity
was determined using Dual-Luciferase Reporter Assay System10 J. Biol. Chem. (2021) 296 100428(Promega Corporation) and measured using PHERAstar FS
(BMG Labtech Ltd).
Quantitative mass spectrometry
The number of molecules of each SIK isoform was deter-
mined by quantitative mass spectrometry following tandem
mass tag labeling as described for T cells (49). The results for
BMMC, with full details of how the experiments were per-
formed and analyzed have been deposited on PRIDE project ID
PXD020091.
Statistical analysis of the data
Results are presented as mean and standard deviation. Sta-
tistical differences between groups of experimental cells were
assessed by one-way or two-way ANOVA with Dunnett’s or
Sidak’s multiple comparison test as indicated in the
figure legend. The results were considered significant if p <
0.05; n.s. not significant, * p < 0.05, ** p < 0.01, *** p < 0.001.
Data availability
All mass spectrometry data are available via PRIDE project
ID PXD020091. Data used for generation of the figures in the
paper are available upon request from the corresponding
author (Philip Cohen, p.cohen@dundee.ac.uk) or the first
author (Nicola Darling, n.j.darling@dundee.ac.uk).
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